The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2017
Price : $35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Altitude sickness; Pulmonary arterial hypertension
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 22 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Dec 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.